Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD106 Phase 1 SAD and MAD Study in Healthy Participants
NCT07471932Phase 1Recruiting
- Sponsor
- Almirall
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LAD106 in atopic dermatitis (AD) (12 arms), sponsored by Almirall. Primary endpoint: Treatment-emergent Adverse Events at Day 104. Started Feb 2026; status: recruiting.
02
Drugs
LAD106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07471932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471932.